http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3652338-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73b46a19d9635f31a98d8919333159f4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2018-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4cfc35cad5695bb9dfbf8c00498a6c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e4f9c786a99dd8ef9c40074f992f668 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d6740612fcf21a9168f1d54a62bc6c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23322bdd32f17adb966a9cd51aa12b30 |
| publicationDate | 2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3652338-A1 |
| titleOfInvention | Method for predicting responsiveness to immunotherapy |
| abstract | The present invention relates to the field of cancer diagnosis and therapy. In particular, the invention relates to a method for predicting sensitivity to immunotherapy in a subject having a neoplastic disease, the method comprising: (A) determining the level of methylation of a gene or fragment thereof; selected from the group consisting of interoxin neuronal intermediate filament protein alpha (ΓΝΑ), protein tyrosine phosphatase, type C receptor-associated protein (PTPRCAP), semaphorin 3B (SEMA3B), a member of the kelch- like 6 (KLHL6), and a member of the Ras 1 association domain family (RASSF1) in a sample from the subject, hypomethylation of the gene or fragment thereof in the sample indicating that the subject will be sensitive to immunotherapy; or hypermethylation of the gene or fragment thereof in the sample indicating that the subject will not be susceptible to immunotherapy; or (B) (i) determining a methylation profile of at least two genes or fragments thereof selected from the group consisting of IN A, PTPRCAP, SEMA3B, KLHL6, and RASSF1 in the sample from topic ; (ii) comparing the methylation profile as determined in (i) with a reference methylation pattern, said reference methylation pattern representing a known sensitivity to immunotherapy; (iii) detecting a deviation or gap between the methylation profile as determined in (i) and said reference methylation profile; and (iv) attributing said finding of deviation or non-deviation to a particular prediction of the subject's sensitivity to immunotherapy. |
| priorityDate | 2017-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.